A Phase II Prospective Trial of mXELOXIRI Reintroduction for mCRC

  • STATUS
    Recruiting
  • End date
    Jun 1, 2023
  • participants needed
    91
  • sponsor
    First Affiliated Hospital of Zhejiang University
Updated on 26 January 2021

Summary

The objective is to evaluate the efficacy and safety of reintroduction of modified XELOXIRI combined with molecular targeted drug in patients with metastatic colorectal cancer (mCRC)

Description

It is an investigator-initiated, single institution, prospective, single-arm clinical study to evaluate the efficacy and safety of reintroduction of modified XELOXIRI combined with bevacizumab as first-line therapy in patients with unresectable mCRC. Eligible patients will receive 12 cycles of mXELOXIRI with bevacizumab and then MDT will be initiated to determine whether to perform a surgery or receive the maintenance therapy until disease progression (PD). At the time of PD, patients will re-introduce XELOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 12 cycles.

Details
Condition Unresectable Metastatic Colorectal Carcinoma
Treatment Capecitabine-Oxaliplatin-Irinotecan-Bevacizumab Combination
Clinical Study IdentifierNCT04508452
SponsorFirst Affiliated Hospital of Zhejiang University
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Personal written informed consent is obtained after the study has been fully explained
Histologically confirmed colon or rectal adenocarcinoma
Excluding appendix cancer and anal canal cancer
\. Clinically unresectable
\. Borderline resectable liver metastases of colorectal cancer considered to
have poor-risk disease not deemed to be suitable for upfront resection if they
had one or more of the following features assessed by a local
multidisciplinary team: more than four metastases, location and distribution
of metastatic disease within the liver unsuitable for resection with clear
margins (e.g. involvement of both lobes of liver, invasion of intrahepatic
vascular structures), extent of liver involvement precluding resection with
adequate post-resection residual liver parenchyma volume for viable liver
function in the immediate postoperative period, and inability to retain
adequate vascular inflow and outflow to maintain viable liver function
\. Age at enrollment is >= 18 and <= 75 years
\. Life expectancy of at least 12 weeks
\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of
or 1
\. .Vital organ functions meet the following criteria within 14 days before
enrollment
If multiple test results are available in that period, the results closest to
enrollment will be used. No blood transfusions or hematopoietic factor
administration will be permitted within 2 weeks before the date on which
measurements are taken
i. Absolute neutrophil count (ANC): 3,000 /cu.mm ii. Platelet count: 10.0
cu.mm iii. Hemoglobin concentration: 8.0 g/dL iv. Prothrombin time (PT)
activated partial thromboplastin time(APTT): 1.5 times upper limit of normal
(ULN) v. Total bilirubin: 1.5 times ULN (3 times ULN for metastases to
liver).Aspartate aminotransferase (AST), Alanine aminotransferase (ALT): 2.5
times ULN (5 times ULN for metastases to liver)
vi. Serum creatinine: 1.5 times ULN, or creatinine clearance: 30 mL/min

Exclusion Criteria

Previous chemotherapy for other malignancies 2.Clinically resectable 3.Major surgical procedure within 28 days prior to study treatment initiation (such as open chest, laparoscopy, thoracoscopic surgery, laparoscopic surgery), unless only colostomy is performed; open biopsy or suturing for major trauma within 14 days of study treatment initiation; or planned major surgical procedure during the study (open chest, laparoscopy) ("major surgical procedures" does not include central venous (CV) port insertion) 4.Have received any experimental therapy (such as take part in another clinical study) within 4 weeks before treatment; 5.Receiving immunotherapy, chemotherapy, radiotherapy (except palliative radiotherapy), or hormonotherapy, which are not included in study protocol; 6.Untreated brain metastases, spinal cord compression, or primary brain tumor; 7.Pregnant, breastfeeding, positive pregnancy test (women who have menstruated in the last year will be tested), or women who are unwilling to use contraception; men who are unwilling to use contraception during the study 8.Any of the following comorbidities i. Uncontrolled hypertension ii. Uncontrolled diabetes mellitus iii. Uncontrolled diarrhea iv. Peripheral sensory neuropathy (Grade 1) v. Active peptic ulcer vi. Unhealed wound (except for suturing associated with implanted port placement) vii. Other clinically significant disease (such as interstitial pneumonia or renal impairment) 9.Subjects with known allergy to the study drugs or to any of its excipients. 10.Any indication of contraindications to chemotherapy; 11.Other active malignancies (synchronous malignancies, and asynchronous malignancies separated by a 5-year disease-free interval) (excluding malignancies that are expected to be completely cured, such as intramucosal carcinoma and carcinoma in situ) 12.Patients are receiving CYP3A4 strong inducer, including but not limited to aminoglutethimide, bexarotene, bosentan, carbamazepine, dexamethasone, efavirenz, fosphenytoin, griseofulvin, modafinil, nafcillin, nevirapine, oxcarbazepine, phenobarbital, diphenylhydantoin, primidone, rifabutin, rifampicin, rifapentine, hypericum perforatum; 13.The investigator judges that patients can not finish the clinical study due to medical, social, or psychological reasons, or can not sign a valid informed consent; 14.Patients with parenchymal organ transplantation who need to receive immunosuppressive therapy; 15.Evidence of HIV infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note